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Endovascular obliteration of saphenous vein
reflux: A perspective
E. John Harris, Jr, MD, Stanford, Calif
Successful treatment of superficial venous insufficiency
will most often necessitate correction of saphenous vein
reflux. Ligation of the saphenous vein at the saphenofemo-
ral junction, with or without excision of varicosities, has not
proven to be a durable treatment because reflux will con-
tinue in the saphenous vein, fed by incompetent branch
veins of the saphenous trunk.1 Stripping of the greater
saphenous vein to the below-knee level has proven to be a
more successful method of treating greater saphenous vein
reflux and has been shown to reduce the risk of reoperation
for recurrent varicosities over high ligation alone.2 Al-
though stripping of the greater saphenous vein has been
well accepted by most vascular surgeons, the postoperative
morbidity, mostly pain and bruising, and the activity limi-
tations recommended after surgery are less than ideal from
a patient’s perspective and leave ample room for improve-
ment. It is in this context that a hopeful new device was
developed to control saphenous vein reflux with minimal
patient discomfort and early return to full activity, the
VNUS Closure catheter (VNUS Medical Technologies,
Inc, Sunnyvale, Calif).
Controlled collagen denaturation of incompetent su-
perficial veins to ablate or reduce venous luminal diameter
is not a new idea.3,4 However, the use of radio frequency
(RF)–resistive heating of the vein wall, controlled with vein
wall temperature and impedance feedback, is a novel idea
that led to the development of VNUS Medical Technolo-
gies, Inc (Sunnyvale, Calif), the startup company responsi-
ble for the Closure catheter. The Closure catheter was
developed alongside failed attempts to use RF energy to
restore valvular competence in incompetent veins with the
Restore catheter. The Restore catheter was unable to pre-
cisely control this RF energy and reliably shrink the dilated
veins sufficiently to restore valvular competence. The Re-
store method was plagued by progressive postprocedural
valve enlargement during follow-up.5 An exciting new
device, the VNUS RF catheter or Closure device, was first
introduced in Europe in 1998 and received Australian and
US Food and Drug Administration approval in March
1999.
The Closure system consists of a dedicated, micropro-
cessor-controlled, bipolar generator and catheters with col-
lapsible electrodes that are introduced into the vein lumen.
Once introduced, the electrodes are energized to destroy
the intima and contract the vein wall so that it will undergo
fibrous obliteration.6 This Closure System offers two
sheathable electrode catheters, 1.7 mm (5F) and 2.7 mm
(8F), which allow RF obliteration of veins from 2 to 12 mm
in diameter. These catheters provide rings of resistive vein-
wall heating of 6 to 8 mm in length, and measured with-
drawal of the catheter along the length of the vein at the
recommended rate of 3 cm/min will effect closure. The
operator selects the treatment temperature, typically 85° C,
and the generator monitors the catheter-vein wall imped-
ance to maintain that temperature.
The catheter can be inserted into the saphenous vein
through a venipuncture sheath either antegrade at the
medial calf or retrograde at the saphenofemoral junction
and either percutaneously or through open exposure of the
vein. Proper positioning of the catheter can be determined
with palpation or fluoroscopy, but most operators prefer-
entially use ultrasonic imaging. The limb to be treated then
is elevated and exsanguinated with an Esmarch’s bandage
applied from toes to the groin. The electrodes then are
unsheathed and catheter-vein wall impedance assessed to
assure proper vein wall contact in the compressed saphe-
nous vein. In thin patients, subcutaneous infiltration of
either normal saline solution or local tumescent anesthetic
is essential to prevent skin burns when the treated vein is
very superficial. In most procedures, completion ultra-
sound scan imaging is performed to identify areas with
persistent flow that can be retreated.6
A multicenter registry has emerged from the experience
with the Closure catheter, and several reports from this
registry have been presented at meetings, with seven pub-
lished reports to date,5-12 before this current report.13
None of these eight reports includes the entire prospective
registry, but rather various subsets of patients evaluated
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during the “learning curve” of the procedure are reported
in the various manuscripts, often with overlapping patients
in different manuscripts at various follow-up intervals. Al-
though 31 centers participated in the registry, one center’s
data have always been excluded for protocol violations and
eight centers did not provide 12-month or longer fol-
low-up data.12
The authors of this latest version of the VNUS Closure
Registry continue to confuse us with subsets of patients
from the much larger prospectively defined registry that has
not been completely reported to date. A recent report
published in this issue of the Journal documents results
collected from the registry for patients treated between
February 1998 to June 2000,13 with follow-up data col-
lected through January 2002. There are 31 sites in Europe,
Australia, and the United States, with the one site excluded
for protocol violations. At these 30 centers, 286 patients
were enrolled in the study, with 319 treated limbs and with
follow-up recorded through January 2002. Only 232 limbs
have at least 12-month follow-up, and 142 limbs have
24-month follow-up. Of these 142 patients now reported
with 24-month follow-up, 22% did not have duplex scan
data obtained at 12 months. The authors of this registry
paper claim patients were excluded from analysis because of
lack of “follow-up data at each follow-up opportunity,” yet
it appears 20% of the 24-month follow-up data were incom-
plete but included for analysis. Where have all the treated
patients gone in the 4 years since this device was first used in
Europe? Follow-up for recurrent venous reflux is critical
because recurrent reflux after traditional surgical proce-
dures is seen in as many as 20% to 30% of patients and
recurrent reflux appears to increase over time. Similar rates
of recurrent reflux have been found both in series of pa-
tients followed systematically and in series of patients re-
ferred for further evaluation after prior surgery.3 In their
recent registry paper,13 the authors acknowledge that fol-
low-up was a problem. One could suggest that patients
who are more symptomatic may be more likely to return for
follow-up than patients with no residual symptoms. An-
other more skeptical possibility is that patients with bad
results are frustrated and are less likely to return for follow-
up, whereas patients with good results are happy and want
to return to share their enthusiasm. A significant number of
patients lost to follow-up could greatly influence the results
in this registry study, and it is concerning that a rigid
prospective follow-up protocol is implied but in fact is not
followed.
Complete occlusion of the RF-treated saphenous vein
is seen in 93.4% of limbs at 1 week, 86.1% of limbs at 6
months, 83.6% of limbs at 12 months, and 85.2% of limbs
at 24 months.13 Compare these numbers with an earlier
registry report6 published in June 2000, in which 25 reg-
istry sites reported 301 treated limbs with a mean follow-up
period of 4.9 months. In this manuscript, 67 limbs had
adjunctive high ligation and could not be compared with
those without adjunctive high ligation, so 234 limbs at 25
registry sites had the endovenous RF obliteration of the
saphenous vein alone. Success of closure was 96% acutely
(11 of 301 acute failures), but this success rate was not
broken down with regard to adjunctive high ligation versus
none. At the mean follow-up period of 4.9 months, recan-
alization of the greater saphenous vein for more than 5 cm
was seen in 21 patients, again not categorized by high
ligation status, so that in only 89% of limbs in this series
treated with endovenous RF ablation (269 of 301 limbs)
did the greater saphenous vein remain obliterated at a mean
follow-up period of 4.9 months. It appears that the success
of RF obliteration of the greater saphenous vein is decreas-
ing with longer follow-up. In a more recent registry publi-
cation, there is a suggestion that centers with more thor-
ough follow-up account for the better results. In centers
with 90% or more follow-up compliance, there was a 91.6%
saphenous occlusion rate at 12 months, and in centers with
less than 90% follow-up compliance, there was an 81.9%
saphenous occlusion rate at 12 months.12 This type of data
reporting forms the basis of my concerns: why should
follow-up compliance influence saphenous occlusion rates?
Is there a significant learning curve, with centers of excel-
lence capable of 90% occlusion rates at 24 months but
centers with less experience realizing 50% occlusion rates at
24 months? One just does not know with the data as
reported to date.
The promise of this technique centers on a central
question: is this saphenous obliteration permanent? Unfor-
tunately, in comparing this recent report13 with the previ-
ously reported Registry series,5-12 the number of durable
saphenous vein occlusions does appear to decrease over
time. The importance of any distinctions between complete
occlusion, near complete occlusions, and recanalization for
the Closure technique remains unclear yet may become
more important with increasing follow-up. The freedom
from saphenous reflux of 94% at 12 months and 92% at 24
months suggests near complete and complete occlusions of
the saphenous vein will prevent reflux.13 Because 59% of
patients had adjunctive phlebectomy, varicosity-free rates
are not a true marker for failure of the VNUS device and
more likely reflect technical error and incomplete phlebec-
tomy rather than failure of the Closure technique.13
Clearly, the VNUS closure device is well tolerated with
minimal short-term and intermediate-term morbidity. Also
clear is that this RF saphenous obliteration therapy is di-
rected at patients with minimal venous insufficiency, CEAP
clinical classifications 0, 1, and 2 predominantly. One
would expect good clinical outcomes as assessed with
symptom severity scores in this subset of patients, and
indeed excellent clinical outcomes have been reported, with
greater than 90% of patients with improved symptom se-
verity scores and 96% patient satisfaction with the proce-
dure at 1 year. Yet there is no control for a placebo effect,
and with minimal preprocedural symptoms, how can one
be sure there is not a placebo effect with regard to symptom
severity score with the VNUS catheter? The registry data
were prospectively defined, yet data collection was not
blinded so patient satisfaction data may be biased.
How does the VNUS Closure technique fare in patients
with a significant number of associated incompetent perfo-
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rators? Are these the patients who are recanalizing by 1
year? This current report12 includes 53 patients with CEAP
clinical classification 4, 5, or 6; yet we do not know how this
subset of patients, likely to have incompetent perforators
and saphenous incompetence, compared with the overall
results?
I continue to be intrigued by this innovative new
therapy, the VNUS Closure catheter. However, in spite of
the nine publications, with overlapping treated patients, I
remain disappointed by the incompleteness of the results
reported to date. In a company expending significant
amounts of capital for promotional activities, there should
be sufficient funds for a thorough, well-documented, pro-
spective trial, performed by unbiased observers, hopefully
with a randomized control arm of selective saphenous vein
stripping and phlebectomy, to prove to us all the value of
this technique. The serial refinement of the endovenous RF
ablation technique and avoidance of learning curve failures
have been offered as reasons for delaying the start of this
important trial, yet valuable information about the inter-
mediate-term outcome of these early treated patients re-
mains missing. In the recent manuscript, we are finally told
that such a trial is underway, and I applaud VNUS for this
effort and I anxiously await the results. Only these data will
establish the true efficacy of this new technique.
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